Merck & Co. stock gains on mRNA melanoma data and new cholesterol drug approval

Merck & Co. stock is trading above analyst consensus as investors react to strong Phase 3 melanoma vaccine results and fresh FDA approval for an oral cholesterol drug, underscoring the pharma giant’s oncology and cardiometabolic pipeline strength.

Merck & Co., Inc. (ISIN US58933Y1055) stock was quoted at 149.85 USD as of September 2, 2026 on the New York Stock Exchange, with the shares moving in a range between 147.76 and 151.68 USD during the session according to market data, keeping the large-cap pharma group in focus for investors who follow big oncology and cardiometabolic names.

mRNA melanoma trial boosts Merck’s oncology profile

The current investor narrative around Merck & Co. stock is dominated by the company’s individualized mRNA-based melanoma program, which has delivered positive long-term Phase 3 results when combined with its PD-1 checkpoint inhibitor Keytruda, according to recent clinical data summaries.

At the 2026 meeting of the American Society of Clinical Oncology, researchers presented five-year results from a randomized trial in which high-risk melanoma patients who had undergone surgery received either Keytruda alone or Keytruda plus a personalized mRNA vaccine; adding the vaccine reduced the relative risk of recurrence or death by 49 percent and reduced the relative risk of distant metastasis or death by 59 percent compared with Keytruda alone, illustrating how the combination strengthens the company’s oncology moat in long-term follow-up.

For investors, the quantified risk reduction is critical: a 49 percent lower likelihood of recurrence or death and a 59 percent drop in distant metastasis or death compared with Keytruda monotherapy suggest that Merck & Co. could lock in durable revenue streams in melanoma if regulators translate these statistically robust outcomes into broader approvals, and the data also support the company’s broader thesis that individualized mRNA therapeutics can extend the life cycle of established immuno-oncology drugs.

Market commentary highlights that Merck & Co. shares have reacted to the melanoma news in recent weeks, with the stock up double digits year-to-date as investors position for future combination-therapy revenues and for potential label expansions that could turn this platform into a multi-billion-dollar franchise.

New oral PCSK9 approval broadens cardiometabolic reach

Alongside oncology, Merck & Co. has added a fresh cardiometabolic pillar with the approval of LIPFENDRA, described as the first oral PCSK9 inhibitor for cholesterol management, according to an analysis by Simply Wall St that tracks US Food and Drug Administration decisions.

PCSK9 inhibition has traditionally required injectable biologic drugs, so an oral PCSK9 agent opens a new segment where Merck & Co. can compete on convenience and adherence for adults with hypercholesterolemia, and this potentially expands the company’s addressable market beyond patients who accept injections.

Investors watching Merck & Co. stock interpret the oral PCSK9 approval as a way to diversify revenue beyond oncology; a large pool of patients with elevated LDL cholesterol could support recurring prescription volumes, and if the company can demonstrate non-inferiority or superiority versus injectable PCSK9 therapies in head-to-head trials, it may capture share from established competitors and add incremental revenue growth on top of its cancer business.

Sector observers also point out that combining a scalable oral agent like LIPFENDRA with Merck & Co.’s established cardiovascular portfolio could improve average revenue per patient and deepen relationships with physicians in cardiology and primary care, which is strategically relevant as payers increasingly focus on outcomes and medication adherence.

Analyst view, dividend and valuation context

According to an aggregated analyst overview cited by an ad-hoc-news.de corporate-news summary that compiles data from MarketBeat and other portals, Merck & Co. currently carries a consensus rating of Moderate Buy, with an average price target of 147.60 USD per share; with the stock quoted at 150.17 USD as of September 1, 2026 in New York trading, the shares are trading modestly above this consensus target, by around 1.7 percent, indicating that expectations for pipeline progress and earnings growth are already partially reflected in the valuation.

The same data compilation notes that Merck & Co. management has guided for fiscal year 2026 earnings per share in a range of 2.66 to 2.76 USD, which provides a fundamental anchor for the valuation; if the company were to deliver EPS at the top end of the range, the guidance implies growth compared with historical levels, and investors can benchmark this range against the current share price to derive an implied forward price-earnings multiple.

Merck & Co. also supports its equity story with a 3.40 USD annualized dividend per share, according to the ad-hoc-news.de summary drawing on dividend data, which translates into a visible cash-return component; with the stock around 150 USD, that dividend corresponds to a yield of roughly 2.3 percent, providing investors with a combination of income and potential capital appreciation supported by the company’s oncology and cardiometabolic pipeline.

Market data compiled by Yahoo Finance shows that Merck & Co. announced a regular cash dividend of 0.85 USD per share with an ex-dividend date of September 15, 2026, which fits into the annualized 3.40 USD payout profile and gives investors a concrete near-term cash-flow date to consider when planning entry or exit points around the distribution.

From a market-capitalization perspective, Merck & Co. is described in the ad-hoc-news.de corporate-news article as having a market value of about 377,000,000,000 USD as of September 1, 2026, highlighting the scale of the company within global pharmaceuticals; for comparison, many mid-cap peers operate at well below 50,000,000,000 USD, which underscores that Merck & Co. sits firmly in the large-cap bracket where liquidity and index inclusion can attract institutional investors.

Keytruda and LIPFENDRA as representative products

In the product dimension, Keytruda remains Merck & Co.’s flagship immuno-oncology drug and continues to drive a substantial portion of the company’s revenue, particularly in indications such as melanoma, lung cancer and other solid tumors where PD-1 blockade has become standard of care; the recent melanoma mRNA trial results effectively extend the Keytruda franchise by demonstrating that adding a personalized vaccine can significantly cut the risk of recurrence and distant metastasis compared with Keytruda alone.

The company’s newly approved LIPFENDRA oral PCSK9 inhibitor adds a cardiometabolic product that could become a cornerstone of Merck & Co.’s cholesterol-management portfolio; by offering an oral alternative in a class previously dominated by injectable biologics, Merck & Co. aims to reach a broader population of patients who prefer pills over injections, and if the drug sees strong uptake among adults with hypercholesterolemia, it could provide a meaningful incremental revenue stream alongside Keytruda and other established medicines.

Stock price level and investor takeaway

Merck & Co. stock last traded at 149.85 USD as of September 2, 2026 on the New York Stock Exchange, based on a Robinhood quote that also shows an intraday trading range between 147.76 and 151.68 USD and a session move of 1.4 percent above the low and 1.2 percent below the high, with trading volume of 9.86 million shares versus an average volume of 14.02 million, illustrating a moderately active session with the price sitting slightly above the average analyst target of 147.60 USD but below the recent intraday peak of 151.68 USD.

Merck & Co. stock key data

• Company: Merck & Co., Inc.
• ISIN: US58933Y1055
• Ticker: MRK
• Trading venue: NYSE
• Price (as of September 2, 2026): 149.85 USD
• Market capitalization: 369,930,000,000 USD (as of September 2, 2026)
• Sector / Industry: Pharmaceuticals / Biotechnology
• Index membership: Dow Jones Industrial Average, S&P 500